Sun Pharmaceutical Industries Ltd

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 22 May 2026.

 Sun Pharmaceutical Industries (Sun Pharma) announced that CRISIL has reaffirmed the rating of the company's long term bank facilities at CRISIL AAA and short term bank facilities and commercial paper at CRISIL A1+. CRISIL has placed the 'Crisil AAA' rating on the long-term bank facilities on 'Rating Watch with Developing Implications'. This rating action follows Sun Pharma's announcement dated 27 April 2026, about signing a definitive agreement to acquire Organon & Co. (announcement). CRISIL has further communicated that it will remove the rating from watch and announce its final rating action post a comprehensive assessment of this acquisition. Further, ICRA has reaffirmed the rating on the long-term bank facilities for Sun Pharma, at ICRA AAA; Stable and short-term bank facilities and commercial paper at ICRA A1+ after taking note of the announcement.

Sun Pharmaceuticals has entered into a definitive agreement under which the company will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes more than 70 products across Women's Health and General Medicines, which includes biosimilars, commercialized across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach. Together, Organon's General Medicines and Women's Health franchise reflect the company's commitment to advancing access and affordability for communities around the world. The proposed acquisition of Organon is aligned with Sun Pharma's strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma's entry into biosimilars as a Top-10 global player. Organon's portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma's existing strengths and enhance long‑term value creation. Upon successful consummation of the transaction, Sun Pharma is poised to be: - Among the top 25 global pharmaceutical companies with combined revenue of US$ 12.4 billion - A leading player in Established Brands/Branded Generics - A more Innovative Medicines focused company with 27% revenue share - A top 3 company in global Women's Health, creating a commercial platform for future growth - The 7th Largest global biosimilar player - A company with presence in 150 countries, with 18 large markets, each generating over US$ 100 million revenues - A stronger cash generating company with EBITDA and cash flow set to nearly double, supporting deleveraging from post transaction Net Debt/EBITDA of 2.3x. For the year ended 31st December, 2025, Organon reported US$ 6.2 billion in revenue and Adjusted EBITDA of US$ 1.9 billion. Organon had debt of US$ 8.6 billion and cash balance of US$ 574 million. Organon recently closed on a divestiture of a product for which it received an upfront payment of $440 million, the net proceeds of which will further contribute to its March 31, 2026 cash balance.

According to the company's exchange filing, Sun Pharma would acquire 100% of Organon's issued and outstanding shares for cash at a price of $14 per share, aggregating to approximately $3.99 billion in total equity value. The company plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is expected to close in early 2027. Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes more than 70 products across Women's Health and General Medicines, which includes biosimilars, commercialized across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach. The proposed acquisition of Organon is aligned with Sun Pharma's strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma's entry into biosimilars as a Top-10 global player. Organon's portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma's existing strengths and enhance long term value creation. The combined entity would be among the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. It would also become a stronger cash generating company with EBITDA and cash flow set to nearly double, supporting deleveraging from post transaction net debt-to-EBITDA of 2.3 times. The transaction has been approved by the boards of directors of Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. Dilip Shanghvi, executive chairman of Sun Pharma, said: 'Organon's portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.' Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25.

Sun Pharmaceutical Industries announced the incorporation of a subsidiary, 'Sun Pharma America, Inc.,' in the United States of America on 23 April 2026.

Sun Pharmaceutical Industries Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1689.8, down 0.22% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.67% on the day, quoting at 22864.2. The Sensex is at 73776.78, up 0.62%.Sun Pharmaceutical Industries Ltd has eased around 6.51% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has eased around 5.19% in last one month and is currently quoting at 21808.4, down 0.3% on the day. The volume in the stock stood at 22.99 lakh shares today, compared to the daily average of 28.77 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1698, down 0.19% on the day. Sun Pharmaceutical Industries Ltd jumped 1.41% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.The PE of the stock is 93.16 based on TTM earnings ending December 25.

The company said Noveltreat is indicated for chronic weight management in adults, to be used alongside a reduced-calorie diet and increased physical activity. It is available in five dose strengths, 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity, on the other hand, is indicated for adults with insufficiently controlled Type 2 diabetes mellitus as an adjunct to diet and exercise. It is available in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL. The company stated that both therapies are priced significantly lower than the innovator brand, with weekly treatment costs ranging from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity. Sun Pharma said the products are delivered through user-friendly, pre-filled pen devices. Noveltreat features a concealed needle designed to reduce injection-related anxiety and improve safety and dosing accuracy, while Sematrinity is offered in a multi-dose pen format with a smooth dialer for flexible and precise dose administration. The pens have been developed by global pharmaceutical device suppliers and are manufactured in Europe. Sun Pharma highlighted that GLP-1 receptor agonists, including semaglutide, are widely used for the treatment of Type 2 diabetes and obesity, offering benefits such as improved glycaemic control and reduced cardiovascular and renal risks. Citing data from the National Family Health Survey-5 (NFHS-5), the company noted that nearly one in four Indians aged 15'49 is overweight or obese, with associated risks including metabolic disorders, cardiovascular diseases, and cancer. It also referred to the ICMR INDIAB study (2023), which estimated that over 101 million people in India are living with diabetes, with a significant proportion failing to achieve glycaemic targets, underscoring the need for effective treatment options and comprehensive disease management. Kirti Ganorkar, managing director, Sun Pharmaceutical Industries, said, 'With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines. To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey'. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. The counter rose 1.90% to settle at Rs 1,777.45 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity and is available in five dose strengths ' 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet & exercise and is available in two dose strengths ' 2 mg/1.5 mL and 4 mg/3 mL. Priced significantly lower than the innovator brand, weekly therapy costs, from initiation to the highest dose, range from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity, supporting greater affordability.Powered by Capital Market - Live

The FDA regulatory action date for this sBLA is expected by 29 October 2026. ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and under the brand name ILUMETRI in Europe, where it is marketed by Almirall. The company said that if approved, the application would add a new indication for ILUMYA. The therapy was approved by the FDA in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Supplemental approvals for scalp and nail plaque psoriasis were granted in April 2024 and December 2025, respectively. ILUMYA has also received marketing authorization from over 55 worldwide health authorities since its original approval, including in India, Japan, the European Union, China, Australia and Canada. Since its approval, ILUMYA has supported nearly 140,000 patients worldwide with durable skin clearance and a well-characterized safety profile through 5 years of clinical follow-up. Additionally, real-world experience has shown strong adherence and persistence, helping patients stay on treatment long-term. ILUMYA has been endorsed widely by dermatologists in the US and globally as a trusted and effective treatment for adults with moderate-to-severe plaque psoriasis. The sBLA is based on the results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies evaluating the efficacy and safety of ILUMYA in adult patients with active psoriatic arthritis. Rick Ascroft, CEO, Sun Pharma North America, said, 'For many people living with psoriatic disease, joint symptoms often add another layer of burden. 'As we continue to strengthen Sun Pharma's innovative portfolio, we look forward to working with the FDA throughout the review process. As the only HHCP-administeredIL-23 biologic, our ambition is that ILUMYA becomes a differentiated first-choice advanced systemic treatment for active psoriatic arthritis.' Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. The counter rose 0.37% to Rs 1,789.15 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1834.9, up 1.22% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.03% on the day, quoting at 24010.95. The Sensex is at 77280.41, down 1.18%. Sun Pharmaceutical Industries Ltd has added around 7% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 4.99% in last one month and is currently quoting at 23253.65, up 1.08% on the day. The volume in the stock stood at 11.22 lakh shares today, compared to the daily average of 23.65 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1831.8, up 0.59% on the day. Sun Pharmaceutical Industries Ltd is up 9.43% in last one year as compared to a 6.86% gain in NIFTY and a 15.08% gain in the Nifty Pharma index.The PE of the stock is 99.67 based on TTM earnings ending December 25.Powered by Capital Market - Live